Pegbelfermin

培贝夫明

Report date: 2022/11/17 20:00:51

Base Information

Drug NamePegbelfermin
Drug Alias NamePEG-FGF21Pegylatedfibroblast growth factor-21 (Ambrx/Bristol-Myers Squibb)FGF-21 mimetic proteins (Ambrx/Merck)ARX-618BMS-986036
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionFibroblast growth factor receptors agonists
TargetsFibroblast growth factor receptors
Therapy Area/IndicationsDiabetes Mellitus, Type 2Liver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesAmbrx Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb Srlcompany
Inactive CompaniesN/A
Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A